← FDA DRUG APPROVALS

FDA ANDA · ANDA206288

DARUNAVIR 600 AND 800 MG

darunavir

Sponsor: CIPLA

APPLICATION
ANDA206288
TYPE
ANDA
ORIGINAL APPROVAL
2023-11-28
LATEST ACTION
2023-11-28
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
None (Tentative Approval), Prescription

Products

DARUNAVIRNone (Tentative Approval)
DARUNAVIR 800MG · TABLET · ORAL
DARUNAVIRNone (Tentative Approval)
DARUNAVIR 400MG · TABLET · ORAL
DARUNAVIRPrescription
DARUNAVIR 600MG · TABLET · ORAL
DARUNAVIRNone (Tentative Approval)
DARUNAVIR 600MG · TABLET · ORAL
DARUNAVIRPrescription
DARUNAVIR 800MG · TABLET · ORAL

Approval history

2023-11-28UNKNOWN · Original · standardLetterAP
2023-11-28UNKNOWN · Original · standardTA
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →